Reaction
Product Container Seal Issue reporting signals
As of the last recalculation, Product Container Seal Issue appears in 1,658 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is TRAVOPROST (PRR 68.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Travoprost | 46 | 68.6 | 69.0 |
| Icosapent Ethyl | 12 | 17.8 | 17.8 |
| Brinzolamide | 11 | 16.0 | 16.0 |
| Brivaracetam | 11 | 15.5 | 15.5 |
| Latanoprost | 51 | 13.1 | 13.1 |
| Testosterone Cypionate | 9 | 12.7 | 12.7 |
| Brimonidine Tartrate | 16 | 11.4 | 11.4 |
| Lifitegrast | 13 | 10.1 | 10.1 |
| Dorzolamide Hydrochloride And Timolol Maleate | 6 | 9.6 | 9.6 |
| Carboxymethylcellulose Sodium | 6 | 8.0 | 8.0 |
| Vibegron | 5 | 7.8 | 7.9 |
| Azelastine | 11 | 7.7 | 7.7 |
| Timolol Maleate | 6 | 7.6 | 7.6 |
| Cannabidiol | 14 | 7.6 | 7.6 |
| Bimatoprost | 16 | 7.0 | 7.0 |
| Guselkumab | 18 | 6.4 | 6.4 |
| Paliperidone Palmitate | 16 | 6.3 | 6.3 |
| Golimumab | 32 | 4.8 | 4.8 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 4.4 | 4.4 |
| Ustekinumab | 33 | 4.1 | 4.1 |
| Brexpiprazole | 5 | 3.8 | 3.8 |
| Emtricitabine And Tenofovir Alafenamide | 3 | 3.3 | 3.3 |
| Erenumab-Aooe | 8 | 1.8 | 1.8 |
| Pimavanserin Tartrate | 6 | 1.4 | 1.4 |